Login to Your Account

Beigene Inks $228M PARP Inhibition Pact with Merck Serono

By Cormac Sheridan
Staff Writer

Wednesday, November 13, 2013
The Merck Serono arm of Merck KGaA is paying an undisclosed up-front payment and could hand over as much as €170 million (US$228 million) more in development and commercial milestones for ex-China rights to Beigene Co. Ltd.’s preclinical PARP inhibitor, Beigene-290.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription